Show MeYes, you can develop moles on your labia. Melanocytes, the pigment-producing cells responsible for moles anywhere on the body, are present in vulvar skin, including the hairless inner surfaces of the labia minora. A mole there is usually benign. The real clinical challenge is not whether moles can appear on the labia, but distinguishing a harmless nevus from vulvar melanoma, which behaves more aggressively than melanoma elsewhere because it is often caught late.
How melanocytes end up in vulvar skin
Moles form when melanocytes cluster instead of spreading evenly through the skin. These cells originate in the neural crest during embryonic development and migrate to the skin, mucous membranes, and uveal tract. During that migration, some melanocytes settle in the vulva, which explains why vulvar nevi can appear on both hair-bearing outer skin and the smooth, mucosal surface of the labia minora.
The labia have a split personality at the tissue level. The labia majora carry keratinized, hair-bearing skin similar to the rest of the body, so nevi there behave like ordinary skin moles. The labia minora and the vestibule are covered by non-keratinized or thinly keratinized mucosa, where nevi look flatter, softer, and less pigmented than their skin counterparts. This difference in surface type is why vulvar nevi are frequently mistaken for something else, and why they are underdiagnosed.
Most vulvar nevi are acquired, meaning they emerge after birth as melanocytes respond to hormones and friction. Congenital nevi, present at birth, also occur on the vulva but are less common. Because the vulva is a hormonally responsive area, moles there can change during puberty, pregnancy, and menopause, which creates noise that complicates visual assessment.
In plain terms: the cells that make moles are already stationed in labial skin, so a mole appearing there is biologically expected, not exotic.
How common vulvar moles are, by the numbers
Benign vulvar nevi are common but poorly counted, because most are asymptomatic and never reach a clinician. Studies of vulvar biopsies place nevi among the most frequent pigmented lesions found on the vulva, and dermatopathology series frequently list intradermal nevi as the leading benign pigmented diagnosis in this region.
Vulvar melanoma is the mirror image: rare but serious. It accounts for roughly 1 to 3 percent of all melanomas in women and about 5 to 10 percent of all vulvar cancers. Incidence estimates in the United States run around 1 to 2 cases per million women per year. The median age at diagnosis is in the 60s, though cases occur in women in their 30s and 40s.
The survival gap is the number that matters. Vulvar melanoma has historically carried a five-year survival of roughly 50 to 60 percent, compared with over 90 percent for early-stage cutaneous melanoma on sun-exposed skin. The gap is driven largely by delayed diagnosis, not by the tumor being inherently more lethal at the same stage.
The counterintuitive detail: sun exposure, the dominant melanoma risk factor elsewhere on the body, plays no meaningful role in vulvar melanoma. The vulva is rarely sun-exposed, so the usual prevention advice about sunscreen does not apply here. Risk is instead tied to age, race, and possibly chronic inflammation, which reframes what surveillance should look like.
What a benign labial mole looks like versus melanoma
Benign vulvar nevi tend to be symmetric, uniformly pigmented, and stable over years. They may be raised or flat, tan, brown, or occasionally pink. On mucosal surfaces, they often appear softer and less sharply defined than skin nevi, which is normal for that tissue.
The warning pattern clinicians use is the ABCDE rule, adapted for the vulva: asymmetry, border irregularity, color variation, diameter over 6 millimeters, and evolution. Evolution is the most reliable single feature. A mole that changes in size, shape, or color over weeks to months deserves evaluation.
Vulvar melanoma often presents as a pigmented lesion on the labia majora or minora, but up to a third are amelanotic, meaning they lack pigment and appear pink, red, or flesh-colored. That variant is especially easy to miss because it does not look like a mole at all. Symptoms like itching, bleeding, or a persistent sore are late signs and should never be the trigger for evaluation.
A plain-language version: stable and even is reassuring, changing and uneven is not, and pink does not mean safe.
| Feature | Benign labial nevus | Vulvar melanoma |
|---|---|---|
| Symmetry | Symmetric | Asymmetric |
| Border | Smooth, regular | Irregular, notched |
| Color | Uniform tan or brown | Multiple shades or amelanotic |
| Size | Usually under 6 mm, stable | Often over 6 mm, growing |
| Change over time | Stable for years | Evolves over weeks to months |
| Symptoms | None | Itching, bleeding, soreness (late) |
| Typical age | Any age | Median in 60s |
Timeline of what happens when a labial mole is evaluated
The path from noticing a mole to a diagnosis follows a fairly predictable sequence. The timeline below reflects typical clinical flow, not a guarantee.
| Stage | Typical timeframe | What happens |
|---|---|---|
| Self-noticing | Day 0 | Mole seen or felt during grooming or self-exam |
| Primary care visit | Days to weeks | Visual inspection, history of change |
| Specialist referral | 1 to 4 weeks | Gynecologist or dermatologist with vulvar experience |
| Biopsy | Same day to 2 weeks | Excisional or punch biopsy of suspicious lesion |
| Pathology result | 3 to 14 days | Benign nevus or melanoma confirmed |
| Staging (if melanoma) | 1 to 3 weeks | Imaging and sentinel node evaluation |
| Treatment start | 2 to 6 weeks | Wide local excision or further staging |
The single biggest variable is the delay before the first visit. Patients often wait months because of embarrassment or because they assume a vulvar mole cannot be dangerous. That delay, not the biology of the lesion, is what most often separates a good outcome from a poor one.
Edge cases that change the picture
Pregnancy is a common trigger for labial mole changes. Hormonal shifts can darken nevi and enlarge them slightly, which is usually benign. But because the change is expected, it can also mask a true malignant transformation, so any mole that grows rapidly or bleeds during pregnancy should be biopsied rather than watched.
Age matters in the opposite direction. Vulvar nevi are common in reproductive-age women and uncommon after menopause, while vulvar melanoma skews older. A new pigmented lesion in a postmenopausal woman therefore carries a higher pretest probability of malignancy and lowers the threshold for biopsy.
Immunosuppression, including from HIV or transplant medications, raises melanoma risk generally and warrants closer surveillance of any pigmented vulvar lesion. A history of prior melanoma anywhere on the body also raises the risk of a second primary, including on the vulva.
Race is a genuine edge case. Vulvar melanoma occurs disproportionately in Black, Hispanic, and Asian women relative to cutaneous melanoma, and it is more often diagnosed at an advanced stage in these groups. The misconception that melanoma only affects fair skin delays diagnosis in exactly the patients who need earlier evaluation.
Misconceptions worth correcting
The most persistent misconception is that a mole on the labia must be an STI. Nevi are not infectious and are not caused by HPV, herpes, or any sexually transmitted agent. They are pigment cell clusters, and they appear regardless of sexual history.
Another is that vulvar moles are always harmless because the vulva is not sun-exposed. Sun exposure is one pathway to melanoma, not the only one. Vulvar melanoma arises through mechanisms that do not require ultraviolet light, so the absence of sun exposure is not protection.
A third is that a mole must be dark to be dangerous. Amelanotic vulvar melanoma is pink or red and accounts for a meaningful minority of cases. Any new, changing, or non-healing lesion on the labia, regardless of color, warrants a look.
A fourth is that biopsy of a vulvar mole is disfiguring or risky. Excisional biopsy of a small labial lesion is a minor procedure with low complication rates, and the information it provides is far more valuable than the cosmetic cost. The caveat here is that biopsy should be done by a clinician experienced with vulvar anatomy, because incomplete sampling of a melanoma can understage it.
Practical actions and thresholds
Self-examination is the highest-yield action, and it takes under a minute. Use a mirror in good light, inspect the labia majora and minora, and note any new or changing pigmented spot. Monthly checks are reasonable for most women, and more frequent checks make sense if you have a personal history of melanoma or are immunosuppressed.
See a clinician within 2 to 4 weeks for any labial mole that is new after age 50, changing in size or color, or over 6 millimeters. Seek evaluation within days, not weeks, for a vulvar lesion that bleeds, itches persistently, or does not heal within 2 to 3 weeks. Request a biopsy rather than observation for any amelanotic (pink or red) lesion that is growing. Do not apply over-the-counter mole removers or acids to vulvar skin; they cause chemical burns and delay diagnosis. Mention any personal or family history of melanoma at the visit, since it changes the threshold for biopsy.
The threshold reconciliation matters here. A 6-millimeter diameter cutoff comes from cutaneous melanoma screening and is a soft trigger for the vulva, not a hard rule, because mucosal nevi can be larger and still benign. The stronger triggers are change over time and new appearance after menopause. When the size rule and the change rule disagree, the change rule wins.
Limitations of what we know
Vulvar nevus research is thin compared with cutaneous nevus research. Most evidence comes from retrospective pathology series, which are subject to selection bias because only biopsied lesions are counted. That means the true prevalence of benign labial moles in the general population is unknown and probably underestimated.
Screening guidance is also unsettled. No major body recommends routine vulvar mole screening, and self-examination has not been validated in a randomized trial the way breast and cervical screening have. The recommendation to check monthly is a reasonable extrapolation from melanoma surveillance principles, not a proven intervention.
Diagnostic thresholds for mucosal melanoma are less standardized than for cutaneous melanoma, and staging systems for vulvar melanoma have evolved over time, which complicates comparison of older survival data to current outcomes. The core message is stable: most labial moles are benign, change is the signal that matters, and delay is the main modifiable risk factor. If you notice something new or different on your labia, the next step is a clinical exam, not a waiting period.